A prospective cohort study of prodromal Alzheimer’s disease: Prospective Imaging Study of Ageing: Genes, Brain and Behaviour (PISA)

Michelle K. Lupton(QIMR Berghofer Medical Research Institute), Gail Robinson(The University of Queensland), Robert Adam(The University of Queensland), Stephen Rose(CSIRO Health and Biosecurity), Gerard J. Byrne(The University of Queensland), Olivier Salvado(CSIRO Health and Biosecurity), Nancy A. Pachana(The University of Queensland), Osvaldo P. Almeida(The University of Western Australia), Kerrie McAloney(QIMR Berghofer Medical Research Institute), Scott D. Gordon(QIMR Berghofer Medical Research Institute), Parnesh Raniga(CSIRO Health and Biosecurity), Amir Fazlollahi(CSIRO Health and Biosecurity), Ying Xia(CSIRO Health and Biosecurity), Amelia Ceslis(The University of Queensland), Saurabh Sonkusare(QIMR Berghofer Medical Research Institute), Qing Zhang(CSIRO Health and Biosecurity), Mahnoosh Kholghi(CSIRO Health and Biosecurity), Mohan Karunanithi(CSIRO Health and Biosecurity), Philip Mosley(The University of Queensland), Jinglei Lv(The University of Sydney), Jessica Adsett(QIMR Berghofer Medical Research Institute), Natalie Garden(QIMR Berghofer Medical Research Institute), Jürgen Fripp(CSIRO Health and Biosecurity), Nicholas G. Martin(QIMR Berghofer Medical Research Institute), Christine C. Guo(QIMR Berghofer Medical Research Institute), Michael Breakspear(QIMR Berghofer Medical Research Institute)
medRxiv
May 8, 2020
10.1101/2020.05.04.20091140
Cited by 10Open Access
Full Text

Abstract

Abstract This prospective cohort study, “Prospective Imaging Study of Ageing: Genes, Brain and Behaviour” (PISA) seeks to characterise the phenotype and natural history of healthy adult Australians at high future risk of Alzheimer’s disease (AD). In particular, we are recruiting mid-life Australians with high and low genetic risk of dementia to discover biological markers of early neuropathology, identify modifiable risk factors, and establish the very earliest phenotypic and neuronal signs of disease onset. PISA utilises genetic prediction to recruit and enrich a prospective cohort and follow them longitudinally. Online surveys and cognitive testing are used to characterise an Australia-wide sample currently totalling nearly 3,000 participants. Participants from a defined at-risk cohort and positive controls (clinical cohort of patients with mild cognitive impairment or early AD) are invited for onsite visits for lifestyle monitoring, detailed neurocognitive testing, blood sample donation, plus functional, structural and molecular neuroimaging. This paper describes recruitment of the PISA cohort, study methodology and baseline demographics. Author Approval All authors have seen and approved this manuscript.

Related Papers

No related papers found

Powered by citation graph analysis